Recurrent Verrucous Carcinoma of the Larynx Completed Phase 2 Trials for Bortezomib D-mannitol (DB16741)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00103259 | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Treatment |